Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04826315 Withdrawn - Cancer Clinical Trials

Cancer and Mild Cognitive Impairment a Patient-Caregiver Behavioral Intervention

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to see whether programs that include both a patient and their spouse or a patient and family caregiver (known as a dyad) are helpful for families in which one member of the dyad has cancer and mild memory difficulties and/or concerns. Participant and their spouse or participant and their family caregiver will have six, 60-minute video-conference sessions which will be scheduled at their convenience. The investigator will loan participants a tablet computer (iPad) to use for videoconferencing and train the participant in its use. Participant and their spouse or participant and their family caregiver will complete three assessments - one before starting the sessions, one after the sixth session, and one after 1 month. Each assessment will include surveys, which the participant will complete separately from their spouse or family caregiver. For most people, it will take upwards of 2 - 4 months to complete this study.

NCT ID: NCT04437953 Withdrawn - Cancer Clinical Trials

Avatrombopag for Thrombocytopenia in People With Cancer

Start date: May 27, 2020
Phase: Phase 2
Study type: Interventional

This study will test whether avatrombopag is an effective treatment for thrombocytopenia in people who have both cancer and a liver disease (such as cirrhosis, cholangitis, or hepatitis). Researchers will look at whether giving participants avatrombopag for 3 weeks can raise their platelet levels enough for them to begin chemotherapy. The study will also test whether avatrombopag can continue to be effective against thrombocytopenia while participants are on chemotherapy for 12 weeks or longer. In addition, researchers will determine how safe the study drug is in participants.

NCT ID: NCT04306783 Withdrawn - Cancer Clinical Trials

In-Home Sensor Monitoring of Older Adults With Cancer

Start date: October 31, 2020
Phase: N/A
Study type: Interventional

The investigators propose a pilot study of monitoring a sample of 6 older patients receiving active cancer treatment over a period of 6 months with in-home sensor monitors installed and maintained by Foresite Healthcare. The investigators also propose exploring the beliefs and attitudes of those who are not willing to allow in-home sensor monitoring by asking them to complete a brief survey related to in-home sensor monitoring. The investigators hypothesize that patients will find the equipment acceptable and unintrusive, that changes in home-monitored patient parameters will precede clinical events and that patient trajectories will be more fully characterized with the in home sensors.

NCT ID: NCT04280640 Withdrawn - Cancer Clinical Trials

Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes

Start date: June 2021
Phase:
Study type: Observational

The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in vivo (patients') disease.

NCT ID: NCT04210726 Withdrawn - Cancer Clinical Trials

Effect of Salt Solution Immersion Bath on Cancer in Vivo.

Start date: March 2020
Phase: N/A
Study type: Interventional

This Study evaluates the effectiveness of Hypertonic Saline Bath in reducing the Cancer nodules' size, number and SUVmax.

NCT ID: NCT04016116 Withdrawn - Cancer Clinical Trials

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Start date: December 2019
Phase: Phase 2
Study type: Interventional

Pembrolizumab will have significant clinical activity in patients with Intermediate and high risk MF, advanced PV who have been resistant, failed or are intolerant to JAK2 inhibitor therapy and the activity may be enhanced in combination with JAK2 inhibition by Ruxolitinib; similarly MDS/MPN and CMML patients for who no standard therapies are available will exhibit responses to PD-1 or dual JAK2 and PD-1 treatment. Adding JAK2 inhibitor Ruxolitinib to Pembrolizumab will have significant activity in patients with advanced, progressive HL who failed single agent PD-1 inhibition.

NCT ID: NCT03959046 Withdrawn - Cancer Clinical Trials

GIST in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation

Start date: June 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy of using GIST language when speaking to patients about bone marrow and hematopoietic stem cell transplantation.

NCT ID: NCT03946865 Withdrawn - Cancer Clinical Trials

Reiki Therapy - an Intervention in Hematology/Oncology Cancer Patients Hospitalized

Start date: July 10, 2019
Phase: N/A
Study type: Interventional

Researchers are trying to determine if offering and providing reiki therapy in hospitalized hematology/oncology cancer subjects has any effects on symptoms and feeling during the subjects hospital stay.

NCT ID: NCT03479151 Withdrawn - Cancer Clinical Trials

Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases

HIFU-Bone
Start date: March 16, 2018
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine whether intra- and post-procedural MR changes are indicative of reduction in pain symptom scores. The trial will recruit a cohort of patients with painful bone metastases, who wish to consider MRgHIFU treatment. These patients will be identified in conjunction with the pain and palliative care teams, as well as clinical and medical oncologists. Patients will undergo MRgHIFU treatment using scanning and treatment planning methods that have been established in the patients treated within the multi-centre study. The treatment response rate for the cohort will be recorded. Intra- and post-procedural imaging metrics will be evaluated for their ability to detect tissue changes, which may be indicative of response. Patients will be followed-up for up to 90 days after treatment, and will attend for repeat imaging and pain review at days 30, 60 and 90 after treatment. Any changes in imaging metrics will be compared between responders and non-responders.

NCT ID: NCT03360474 Withdrawn - Cancer Clinical Trials

Implementation of a Delirium Screening

Start date: June 2018
Phase: N/A
Study type: Interventional

The purpose of this project is to improve patient outcomes in individuals affected by cancer, through the implementation of a delirium screening and treatment protocol in the ICU setting. The hypothesis is that patients who receive an accurate and early diagnosis of delirium coupled with a standardized intervention protocol will demonstrate improved patient outcomes as evidenced by fewer days spent in the ICU, fewer days spent in the hospital (overall length of stay) and the need for less sedative medication throughout their ICU stay as compared to patient data prior to the implementation of a delirium protocol.